{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:35:06Z","timestamp":1770143706060,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/jpet.124.002129","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:23:15Z","timestamp":1719505395000},"page":"272-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-766X","authenticated-orcid":false,"given":"Rachel","family":"Luba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Madera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Schusterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kolodziej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002129_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.888903","article-title":"Cannabis for medical use: analysis of recent clinical trials in view of current legislation","volume":"13","author":"Baratta","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.124.002129_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1369-1600.2011.00427.x","article-title":"Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers","volume":"18","author":"Bedi","year":"2013","journal-title":"Addict Biol"},{"key":"10.1124\/jpet.124.002129_bib3","series-title":"Methods of Assessing Reinforcing Properties of Abused Drugs","author":"Bozarth","year":"1987"},{"key":"10.1124\/jpet.124.002129_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.124.002129_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/molpharm.120.000083","article-title":"Molecular mechanisms for the inflammation-resolving actions of lenabasum","volume":"99","author":"Burstein","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.124.002129_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.394","article-title":"Ajulemic acid: potential treatment for chronic inflammation","volume":"6","author":"Burstein","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/jpet.124.002129_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2020.09.008","article-title":"Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis","volume":"20","author":"Chmiel","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1124\/jpet.124.002129_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1124\/jpet.124.002129_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/srep21703","article-title":"The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways","volume":"6","author":"del R\u00edo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.124.002129_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamapsychiatry.2020.1032","article-title":"Perspectives on cannabis research-barriers and recommendations","volume":"77","author":"Haney","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1124\/jpet.124.002129_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ajp.2021.21111138","article-title":"Cannabis use and the endocannabinoid system: a clinical perspective","volume":"179","author":"Haney","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.124.002129_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a signaling cannabinoid receptor 1-G protein complex","volume":"176","author":"Krishna Kumar","year":"2019","journal-title":"Cell"},{"key":"10.1124\/jpet.124.002129_bib13","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"Suppl B","key":"10.1124\/jpet.124.002129_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(82)80031-5","article-title":"Pharmacokinetics, metabolism and drug-abuse potential of nabilone","volume":"9","author":"Lemberger","year":"1982","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.124.002129_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugalcdep.2010.11.019","article-title":"Separate and combined effects of the cannabinoid agonists nabilone and \u03949-THC in humans discriminating \u03949-THC","volume":"116","author":"Lile","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.124.002129_bib16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.124.002129_bib17","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.3390\/molecules28165980","article-title":"Molecular and cellular mechanisms of action of cannabidiol","volume":"28","author":"Martinez Naya","year":"2023","journal-title":"Molecules"},{"key":"10.1124\/jpet.124.002129_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0019-5154.100486","article-title":"Clinical presentation and evaluation of dermatomyositis","volume":"57","author":"Marvi","year":"2012","journal-title":"Indian J Dermatol"},{"issue":"Suppl A","key":"10.1124\/jpet.124.002129_bib19","article-title":"Pharmacokinetics of cannabinoids","volume":"10","author":"McGilveray","year":"2005","journal-title":"Pain Res Manag"},{"key":"10.1124\/jpet.124.002129_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-20825-1_1","article-title":"Endocannabinoids and their pharmacological actions","volume":"231","author":"Pertwee","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.124.002129_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","article-title":"Cannabidiol: state of the art and new challenges for therapeutic applications","volume":"175","author":"Pisanti","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.124.002129_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1124\/jpet.124.002129_bib23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem Biodivers"},{"key":"10.1124\/jpet.124.002129_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101301","article-title":"Cannabinoids and cannabinoid receptors: the story so far","volume":"23","author":"Shahbazi","year":"2020","journal-title":"iScience"},{"key":"10.1124\/jpet.124.002129_bib25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.124.002129_bib26","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.124.002129_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcf.2020.03.015","article-title":"Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis","volume":"19","author":"Tarique","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1124\/jpet.124.002129_bib28","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.124.002129_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/phar.1709","article-title":"Nabilone for the management of pain","volume":"36","author":"Tsang","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1124\/jpet.124.002129_bib30","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/jpet.124.002129_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:37:02Z","timestamp":1739979422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524178019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022356524178019"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002129","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}